Tag:
BCX4208
Latest Headlines
Latest Headlines
BioCryst shares surge on positive IIb study for gout drug
Shares of BioCryst Pharmaceuticals ( $BCRX ) bumped up 12% this morning after the biotech unveiled a set of positive top-line data for its mid-stage gout drug. In a 12-week Phase IIb study of BCX4208,
BioCryst shares surge on positive PhIIa gout data
Shares of Birmingham, AL-based BioCryst Pharmaceuticals ( NASDAQ: BCRX ) surged 15 percent this morning after the developer announced positive data from the interim analysis of a Phase IIa study of its
